Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 81-90 of 171 for Prostate cancer

Edit search filters
  1. An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation In PSMA Positive OMPC. (PSMA-DC)

    Rochester, MN

  2. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 In Combination With Soc, Versus SoC Alone, In Adult Male Patients With MHSPC

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Schedule De-Escalation Of 177Lu-PSMA-617 For The Treatment Of Metastatic Castrate Resistant Prostate Cancer

    Rochester, MN

  4. Therapeutic Plasma Exchange With Enfortumab Vedotin And Pembrolizumab For Treatment Of Bladder Cancers

    Rochester, MN

  5. Diagnostic 68Ga-PSMA-11 PET/CT

    Rochester, MN

  6. Study Of E7386 In Participants With Selected Advanced Neoplasms

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study To Evaluate Precision Pharmacogenomics In Cancer Patients

    Scottsdale/Phoenix, AZ

  8. Highly Selective CDK7 Inhibitor Q901 In Selected Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Study Of Zanzalintinib In Combination With Immuno-Oncology Agents In Participants With Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Study Of Cabozantinib Alone Or In Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer